EcoDrugPlus

60s Ribosomal Protein L37

Ensembl ID : ENSOTSG00005029640
Gene Symbol: LOC112220146
3 Cross references
419 Possible Orthologues:

60s Ribosomal Protein L37-Like

Ensembl ID : ENSOTSG00005018536
Gene Symbol: LOC112262610
3 Cross references
377 Possible Orthologues:

60s Ribosomal Protein L39-Like

Ensembl ID : ENSOTSG00005003308
Gene Symbol: LOC112256380
3 Cross references
176 Possible Orthologues:

60s Ribosomal Protein L4-B-Like

Ensembl ID : ENSOTSG00005000074
Gene Symbol: LOC112218960
3 Cross references
339 Possible Orthologues:

60s Ribosomal Protein L6-Like

Ensembl ID : ENSOTSG00005011140
Gene Symbol: LOC112262754
3 Cross references
481 Possible Orthologues:

60s Ribosomal Protein L8

Ensembl ID : ENSOTSG00005043076
Gene Symbol: LOC112225330
3 Cross references
270 Possible Orthologues:

60s Ribosomal Protein L8-Like

Ensembl ID : ENSOTSG00005026800
Gene Symbol: LOC112242653
3 Cross references
270 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005021616
Gene Symbol: ABL1
1 Cross references
196 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSOTSG00005010698
Gene Symbol: ABL1
3 Cross references
196 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOTSG00005043283
Gene Symbol: ADAM17
3 Cross references
201 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOTSG00005012037
Gene Symbol: ADAM17
3 Cross references
204 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSOTSG00005013854
Gene Symbol: ADAM17
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).